Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)

被引：1
|
作者：
Mustacchi, G.
Bines, J.
Alba, E.
Cortes, P.
Doval, D.
de Ducla, S.
Button, P.
Gligorov, J.
机构：
[1] Univ Trieste, Trieste, Italy
[2] Inst Nacl Canc, Rio De Janeiro, Brazil
[3] Hosp Univ Clin Virgen Victoria, Malaga, Spain
[4] Univ Hosp Santa Maria, Lisbon, Portugal
[5] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
[6] F Hoffmann Roche Ltd, Basel, Switzerland
[7] Roche Prod Ltd, Dee Why, Australia
[8] IC UPMC, APHP Tenon, Paris, France
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P5-15-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-15-06
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer
    Miles, David
    Cameron, David
    Hilton, Magalie
    Garcia, Josep
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2018, 90 : 153 - 155
  • [32] Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).
    Berghoff, A.
    Bartsch, R.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rudas, M.
    Pluschnig, U.
    Wiltschke, C.
    Gnant, M.
    Steger, G. G.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
    Baselga, Jose
    Zamagni, Claudio
    Gomez, Patricia
    Bermejo, Begona
    Nagai, Shigenori E.
    Melichar, Bohuslav
    Chan, Arlene
    Mangel, Laszlo
    Bergh, Jonas
    Costa, Frederico
    Gomez, Henry L.
    Gradishar, William J.
    Hudis, Clifford A.
    Rapoport, Bernardo L.
    Roche, Henri
    Maeda, Patricia
    Huang, Liping
    Meinhardt, Gerold
    Zhang, Joshua
    Schwartzberg, Lee S.
    CLINICAL BREAST CANCER, 2017, 17 (08) : 585 - +
  • [34] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Petzer, Andreas
    Hubalek, Michael
    Petru, Edgar
    Sandholzer, Margit
    Andel, Johannes
    Balic, Marija
    Melchardt, Thomas
    Hauser-Kronberger, Cornelia
    Schmitt, Clemens A.
    Ulmer, Hanno
    Greil, Richard
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [35] Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Conlin, A. K.
    Hudis, C. A.
    Bach, A.
    Moynahan, M.
    Lake, D.
    Forero-Torres, A.
    Wright, G.
    Hackney, M.
    Clawson, A.
    Seidman, A. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Impact of Post-Progression Therapy (PPT) on Survival in AVF2107, a phase III trial of bevacizumab (AVASTIN™) in the first-line treatment of metastatic colorectal cancer
    Hedrick, Eric
    Hurwitz, H.
    Sarkar, S.
    Griffing, S.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 96 - 96
  • [37] A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).
    Mavroudis, D.
    Boukovinas, I.
    Christophyllakis, C.
    Xenidis, N.
    Papakotoulas, P.
    Malamos, N. A.
    Kakolyris, S.
    Polyzos, A.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] LAPATINIB (L) PLUS CAPECITABINE (C) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): AN EXPLORATORY ANALYSIS OF OVERALL SURVIVAL (OS) BASED ON POSTSTUDY THERAPY
    Crown, J. P.
    Casey, M.
    Cameron, D.
    Chan, A.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [39] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6).
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Voskova, Daniela
    Petzer, Andreas L.
    Hubalek, Michael
    Petru, Edgar
    Hartmann, Bernd
    Andel, Johannes
    Balic, Marija
    Ulmer, Hanno
    Melchardt, Thomas
    Mlineritsch, Brigitte
    Greil, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Incidence of selected adverse events (AEs) in phase III studies of bevacizumab (BV) in combination with chemotherapy for the treatment of HER2-negative metastatic breast cancer (mBC)
    Miles, D. W.
    Dieras, V.
    Glaspy, J.
    Brufsky, A.
    Koralewski, P.
    Phan, S. C.
    Robert, N. J.
    EJC SUPPLEMENTS, 2010, 8 (03): : 196 - 196
12345